RIME Therapeutics, a Montreal-based biotech startup focused on peptide-based drug discovery for inflammation and immunology, has been awarded the AbbVie Biotech Innovators Award. This award, funded by AbbVie and in partnership with adMare BioInnovations, provides RIME with one year of lab and office space at the adMare Innovation Centre in Montreal, access to shared equipment, and mentorship from AbbVie's scientific and business leaders. The support aims to accelerate RIME's innovative drug discovery platform and contribute to advancing life sciences in Quebec and Canada. This recognition highlights AbbVie's commitment to fostering early-stage biotech innovation and building a thriving life sciences ecosystem.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
